|
Nov 15
|
Taysha Gene Therapies Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Nov 14
|
Q3 2024 Taysha Gene Therapies Inc Earnings Call
|
|
Nov 14
|
Taysha Gene Therapies Inc (TSHA) Q3 2024 Earnings Call Highlights: Clinical Progress and ...
|
|
Nov 13
|
Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates
|
|
Nov 13
|
Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
|
Nov 12
|
US Penny Stocks To Watch In November 2024
|
|
Oct 3
|
Is Taysha Gene Therapies, Inc. (TSHA) the Best NASDAQ Stock Under $5?
|
|
Sep 26
|
Taysha Gene Therapies Announces Oral Presentation on TSHA-102 in Rett Syndrome at Upcoming 9th World Rett Syndrome Congress
|
|
Jun 25
|
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
|
|
Jun 18
|
Taysha Gene Therapies Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in Ongoing REVEAL Phase 1/2 Trials Evaluating TSHA-102 in Rett Syndrome
|
|
Jun 18
|
Sanofi taps Belharra for immune drug research; AstraZeneca’s new cancer drug falls short
|
|
May 15
|
Taysha Gene Therapies Inc (TSHA) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
|
|
May 14
|
Taysha Gene Therapies, Inc. (TSHA) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 14
|
Taysha Gene Therapies Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
May 7
|
Taysha Gene Therapies to Release First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 14
|
|
May 2
|
Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q1 Earnings? What You Should Know
|
|
May 2
|
Taysha Gene Therapies Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for TSHA-102 in Rett Syndrome
|
|
Apr 29
|
These 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper Sandler
|
|
Apr 20
|
Analysts' Revenue Estimates For Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Are Surging Higher
|
|
Apr 15
|
Certain Biotech Investors Get an Early Look at Results. Is That Fair?
|